國立高雄大學圖資館 |

登入

回首頁

Microbiome in 3P medicine strategiesthe first exploitation guide /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Microbiome in 3P medicine strategiesedited by Nadiya Boyko, Olga Golubnitschaja.
其他題名:	the first exploitation guide /
其他作者:	Boyko, Nadiya.
出版者:	Cham :Springer International Publishing :2023.
面頁冊數:	xv, 425 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Medical microbiology.
電子資源:	https://doi.org/10.1007/978-3-031-19564-8
ISBN:	9783031195648$q(electronic bk.)

Microbiome in 3P medicine strategiesthe first exploitation guide /
Microbiome in 3P medicine strategiesthe first exploitation guide /[electronic resource] :edited by Nadiya Boyko, Olga Golubnitschaja. - Cham :Springer International Publishing :2023. - xv, 425 p. :ill., digital ;24 cm. - Advances in predictive, preventive and personalised medicine,v. 162211-3509 ;. - Advances in predictive, preventive and personalised medicine ;v.1..

Chapter 1: Microbiome in the framework of Predictive, Preventive and Personalised Medicine -- Chapter 2: Artificial Intelligence-based Predictive, Preventive, and Personalised Medicine applied to Bacteraemia Diagnosis -- Chapter 3: Vaginal microbiome and its role in HPV induced cervical carcinogenesis -- Chapter 4: Microbiome in lean Individuals: Phenotype-specific Risks and Outcomes -- Chapter 5: Microbiome and Obesity -- Chapter 6: Pathophysiology-based approach for individualized use of probiotics and prebiotics for metabolic syndrome: implementing predictive, preventive, and personalized medical approach -- Chapter 7: Selection of prebiotic substances for individual prescription -- Chapter 8: Probiotic Administration for the Prevention and Treatment of Gastrointestinal, Metabolic and Neurological Disorders -- Chapter 9: Microbial therapy with indigenous bacteria. From idea to clinical evidence -- Chapter 10: Fecal microbiota transplantation in diseases not associated with Clostridium difficile: current status and future therapeutic option -- Chapter 11: Personalized microbiome correction by application of individual nutrition for type 2 diabetes treatment -- Chapter 12: Pro-, pre- and synbiotic supplementation and oxalate homeostasis in 3PM context: focus on microbiota oxalate-degrading activity -- Chapter 13: In vitro study of specific properties of probiotic strains for effective and personalized probiotic therapy -- Chapter 14: Probiotic concepts of predictive, preventive, and personalized medical approach for obesity: Lactic acid bacteria and Bifidobacteria probiotic strains improve glycemic and inflammation profiles -- Chapter 15: Oral Microbiome and Innate Immunity in Health and Disease: Building a Predictive, Preventive and Personalized Therapeutic approach.

The book analyses microbiome-relevant findings focused on clinical needs providing the roadmap to implement recent achievements in the area representing a valuable contribution to the paradigm shift from reactive to predictive, preventive and personalised medicine (PPPM / 3PM) considered as the most advanced concept in medicine. Already well-acknowledged as well as future advantages of application of pre-, pro- and pharma-biotics are detailed in the book. Socio-economic impacts of the area are considered in the context of the entire spectrum of healthcare services from disease care provided to patients up to health care provided to persons in suboptimal health conditions. Innovative technologies including phenotyping, genotyping, individualised profiling, patient stratification, big data analysis, and multi-omics, amongst others are all involved in the book. The book is unique from view point of multi-professional expertise involved. International network presents more than 10 countries worldwide including Belgium, China, Germany, Israel, Ukraine and USA. The data presented are of great scientific value and of particular importance for educating a broad spectrum of professionals including researchers, healthcare givers, policy makers, business people, policy makers and general population.

ISBN: 9783031195648$q(electronic bk.)

Standard No.: 10.1007/978-3-031-19564-8doiSubjects--Topical Terms:

189151
Medical microbiology.

LC Class. No.: QR46

Dewey Class. No.: 616.9041

Microbiome in 3P medicine strategiesthe first exploitation guide /
LDR:04217nmm a2200337 a 4500 001 639525
003 DE-He213
005 20230202090103.0
006 m d
007 cr nn 008maaau
008 231025s2023 sz s 0 eng d
020 $a 9783031195648$q(electronic bk.)
020 $a 9783031195631$q(paper)
024 7 $a 10.1007/978-3-031-19564-8 $2 doi
035 $a 978-3-031-19564-8
040 $a GP $c GP
041 0 $a eng
050 4 $a QR46
072 7 $a MMFM $2 bicssc
072 7 $a MED052000 $2 bisacsh
072 7 $a MKFM $2 thema
082 0 4 $a 616.9041 $2 23
090 $a QR46 $b .M626 2023
245 0 0 $a Microbiome in 3P medicine strategies $h [electronic resource] : $b the first exploitation guide / $c edited by Nadiya Boyko, Olga Golubnitschaja.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a xv, 425 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in predictive, preventive and personalised medicine, $x 2211-3509 ; $v v. 16
505 0 $a Chapter 1: Microbiome in the framework of Predictive, Preventive and Personalised Medicine -- Chapter 2: Artificial Intelligence-based Predictive, Preventive, and Personalised Medicine applied to Bacteraemia Diagnosis -- Chapter 3: Vaginal microbiome and its role in HPV induced cervical carcinogenesis -- Chapter 4: Microbiome in lean Individuals: Phenotype-specific Risks and Outcomes -- Chapter 5: Microbiome and Obesity -- Chapter 6: Pathophysiology-based approach for individualized use of probiotics and prebiotics for metabolic syndrome: implementing predictive, preventive, and personalized medical approach -- Chapter 7: Selection of prebiotic substances for individual prescription -- Chapter 8: Probiotic Administration for the Prevention and Treatment of Gastrointestinal, Metabolic and Neurological Disorders -- Chapter 9: Microbial therapy with indigenous bacteria. From idea to clinical evidence -- Chapter 10: Fecal microbiota transplantation in diseases not associated with Clostridium difficile: current status and future therapeutic option -- Chapter 11: Personalized microbiome correction by application of individual nutrition for type 2 diabetes treatment -- Chapter 12: Pro-, pre- and synbiotic supplementation and oxalate homeostasis in 3PM context: focus on microbiota oxalate-degrading activity -- Chapter 13: In vitro study of specific properties of probiotic strains for effective and personalized probiotic therapy -- Chapter 14: Probiotic concepts of predictive, preventive, and personalized medical approach for obesity: Lactic acid bacteria and Bifidobacteria probiotic strains improve glycemic and inflammation profiles -- Chapter 15: Oral Microbiome and Innate Immunity in Health and Disease: Building a Predictive, Preventive and Personalized Therapeutic approach.
520 $a The book analyses microbiome-relevant findings focused on clinical needs providing the roadmap to implement recent achievements in the area representing a valuable contribution to the paradigm shift from reactive to predictive, preventive and personalised medicine (PPPM / 3PM) considered as the most advanced concept in medicine. Already well-acknowledged as well as future advantages of application of pre-, pro- and pharma-biotics are detailed in the book. Socio-economic impacts of the area are considered in the context of the entire spectrum of healthcare services from disease care provided to patients up to health care provided to persons in suboptimal health conditions. Innovative technologies including phenotyping, genotyping, individualised profiling, patient stratification, big data analysis, and multi-omics, amongst others are all involved in the book. The book is unique from view point of multi-professional expertise involved. International network presents more than 10 countries worldwide including Belgium, China, Germany, Israel, Ukraine and USA. The data presented are of great scientific value and of particular importance for educating a broad spectrum of professionals including researchers, healthcare givers, policy makers, business people, policy makers and general population.
650 0 $a Medical microbiology. $3 189151
650 1 4 $a Medical Microbiology. $3 273931
650 2 4 $a Health Informatics. $3 274212
650 2 4 $a Metabolic Disease. $3 921012
700 1 $a Boyko, Nadiya. $3 945838
700 1 $a Golubnitschaja, Olga. $3 849799
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Advances in predictive, preventive and personalised medicine ; $v v.1. $3 586807
856 4 0 $u https://doi.org/10.1007/978-3-031-19564-8
950 $a Biomedical and Life Sciences (SpringerNature-11642)